每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，鲁抗医药2月24日晚间发布公告称，近日，山东鲁抗医药股份有限公司控股子公司山东鲁 抗医药集团赛特有限责任公司收到国家药品监督管理局颁发的关于米诺地尔搽剂的《药品注册证书》， 该药品是按照新注册分类3类获批的仿制药，视为通过仿制药质量和疗效一致性评价。产品名称为"米诺 地尔搽剂"。 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：磐石 格隆汇2月24日丨鲁抗医药(600789.SH)公布，公司控股子公司山东鲁抗医药集团赛特有限责任公司（简 称"赛特公司"）收到国家药品监督管理局颁发的关于米诺地尔搽剂（简称"该药品"）的《药品注册证 书》（批件号：2026S00478、2026S00479），该药品是按照新注册分类3类获批的仿制药，视为通过仿 制药质量和疗效一致性评价。 米诺地尔属于钾通道开放类抗高血压药物但具有多毛症的副作用。美国Upjohn公司针对此种不良反应进 行研究发现其溶液外用治疗秃发有明显疗效。1988年9月经美国FDA批准2%米诺地尔外用溶液上市用于 治疗斑秃男性秃发及化疗后秃发，1991年FDA批准可在妇女中使用，1997年FDA批准上市了5%米诺地 尔外用溶液用于男性患者。目前国内有米诺地尔搽剂、米诺地尔酊等相关剂型用于治疗秃发。本品用于 治疗男性型脱发和斑秃。 ...

智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司控股子公司山东鲁抗医药集团赛特有限 责任公司(以下简称"赛特公司")收到国家药品监督管理局颁发的关于米诺地尔搽剂(以下简称"该药品") 的《药品注册证书》(批件号：2026S00478、2026S00479)，该药品是按照新注册分类3类获批的仿制 药，视为通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - The announcement highlights that Tiancon (301263) has received a drug registration certificate for Minoxidil topical solution from the National Medical Products Administration, indicating a significant step in the company's product development and market entry in the hair loss treatment sector [1] Company Summary - Tiancon's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the registration certificate for Minoxidil topical solution, with acceptance numbers CYHS2400976 and CYHS2400977 [1] - The registered product is classified as a Class 3 chemical drug, with specifications of 60ml:1.2g and 60ml:3.0g, and the approval numbers are 国药准字H20263325 and 国药准字H20263326 [1] - The approval conclusion states that the product meets the registration requirements, allowing for its market introduction [1] Industry Summary - Minoxidil is recognized as a topical treatment for hair loss, and the company anticipates growth in the domestic hair loss treatment market due to the rising prevalence of hair loss conditions [1]

Group 1 - The core announcement is that Tianenkang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [2] Group 2 - The approval of the Minoxidil lotion indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [2] - This development may open new avenues for revenue generation and market expansion for the company in the biopharmaceutical sector [2]

Group 1 - The core point of the article is that Guangdong Tianen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [1] Group 2 - The product name is "Minoxidil lotion" [1]

Core Viewpoint - The company TianKang's wholly-owned subsidiary, Huabo Kaisheng, has received a drug registration certificate for Minoxidil topical solution from the National Medical Products Administration, indicating a significant step in the company's product development and market entry in the hair loss treatment sector [1] Company Summary - TianKang's subsidiary has been granted a registration certificate for Minoxidil topical solution, classified as a Class 3 chemical drug, with specifications of 60ml: 1.2g and 60ml: 3.0g [1] - The approval numbers for the drug are Guoyao Zhunzi H20263325 and Guoyao Zhunzi H20263326 [1] Industry Summary - Minoxidil is a commonly used topical treatment for hair loss, and the domestic market for hair loss treatments is expected to grow [1] - Currently, there are 31 companies that have received registration approvals for this drug in the domestic market, indicating a competitive landscape [1] - The future sales performance of the product will be influenced by industry policies and market conditions, which introduces a level of uncertainty [1]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, a commonly used treatment for hair loss [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), is responsible for the registration of Minoxidil [1] - The approval of Minoxidil is expected to enhance the company's product portfolio in the hair loss treatment market [1] Group 2: Industry Insights - Minoxidil is a well-known topical treatment for hair loss, functioning as a vasodilator that relaxes blood vessel walls, facilitating blood flow to the scalp and hair follicles [1] - The drug works by catalyzing the formation of the active metabolite Minoxidil sulfate, which stimulates hair follicle growth and promotes the proliferation of atrophied hair follicles [1]

Core Viewpoint - The announcement indicates that TianKang's wholly-owned subsidiary, Huabo Kaisheng, has received drug registration certificates for Minoxidil topical solution from the National Medical Products Administration, marking a significant step in the company's product offerings in the hair loss treatment market [1] Group 1: Company Developments - Huabo Kaisheng has been granted registration for Minoxidil topical solution in two formulations: 60ml:1.2g and 60ml:3.0g, with approval numbers H20263325 and H20263326 respectively [1] - The product's sales performance is subject to various influencing factors, indicating potential variability in market reception and revenue generation [1] Group 2: Industry Insights - The domestic market for hair loss prevention is projected to grow, with 31 companies currently holding registration for Minoxidil topical solution in China, highlighting a competitive landscape [1]